Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	61.95	53.4	65.49	47.64	38.35	62.9
Revenue Growth (YoY)	62.79%	-18.47%	37.48%	24.22%	-39.03%	15.00%
Cost of Revenue	26.31	24.32	22.98	19.59	16.35	10.87
Gross Profit	35.64	29.08	42.51	28.05	22	52.03
Selling, General & Admin	10.82	12.19	14.96	11.71	12.73	11.15
Research & Development	16.59	12.97	17.09	29.35	29.73	38.17
Operating Expenses	27.41	25.16	32.05	41.06	42.46	49.32
Operating Income	8.23	3.92	10.46	-13.01	-20.46	2.71
Interest Expense	-0.93	-1.06	-3.18	-2.53	-7.52	-9.67
Interest & Investment Income	0.79	1.3	1.29	1.15	0.4	0.44
EBT Excluding Unusual Items	8.09	4.15	8.57	-14.4	-27.58	-6.52
Pretax Income	8.09	4.15	8.57	-14.4	-27.58	-6.52
Income Tax Expense	1.81	1.22	0.25	0.53	-	-
Earnings From Continuing Operations	6.28	2.93	8.31	-14.93	-27.58	-6.52
Net Income	6.28	2.93	8.31	-14.93	-27.58	-6.52
Net Income to Common	6.28	2.93	8.31	-14.93	-27.58	-6.52
Net Income Growth	-	-64.73%	-	-	-	-
Shares Outstanding (Basic)	75	73	68	48	44	29
Shares Outstanding (Diluted)	83	81	82	48	44	29
Shares Change (YoY)	14.25%	-1.66%	70.04%	9.81%	51.43%	96.44%
EPS (Basic)	0.08	0.04	0.12	-0.31	-0.62	-0.22
EPS (Diluted)	0.08	0.04	0.09	-0.31	-0.62	-0.22
EPS Growth	-	-57.71%	-	-	-	-
Free Cash Flow	-3.44	7.39	-2.47	-25.63	-11.74	-26.76
Free Cash Flow Per Share	-0.04	0.09	-0.03	-0.53	-0.27	-0.92
Gross Margin	57.53%	54.46%	64.91%	58.87%	57.37%	82.71%
Operating Margin	13.28%	7.33%	15.97%	-27.32%	-53.36%	4.31%
Profit Margin	10.13%	5.49%	12.69%	-31.33%	-71.92%	-10.37%
Free Cash Flow Margin	-5.56%	13.84%	-3.77%	-53.80%	-30.62%	-42.55%
EBITDA	9.6	5.22	11.65	-11.93	-19.34	4.01
EBITDA Margin	15.49%	9.78%	17.79%	-25.04%	-50.44%	6.38%
D&A For EBITDA	1.37	1.3	1.19	1.09	1.12	1.3
EBIT	8.23	3.92	10.46	-13.01	-20.46	2.71
EBIT Margin	13.28%	7.33%	15.97%	-27.32%	-53.36%	4.31%
Effective Tax Rate	22.42%	29.42%	2.96%	-	-	-
Revenue as Reported	61.95	53.4	65.49	47.64	38.35	62.9

Updated Aug 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q